Boston Scientific Corp.
Chiusa
SettoreSettore sanitario
46.82 -0.76
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
46.6
Massimo
47.05
Entrata | 669M 1.3B |
|---|---|
Vendite | -83M 5.2B |
P/E Media del settore | 20.377 49.052 |
EPS | 0.8 |
Margine di Profitto | 25.774 |
Dipendenti | 59,000 |
EBITDA | 647M 1.6B |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +65.7% upside |
Utili prossimi | 29 lug 2026 |
|---|
Capitalizzazione di Mercato | -18B 72B |
|---|---|
Apertura precedente | 47.58 |
Chiusura precedente | 46.82 |
Notizie sul Sentiment di mercato
By Acuity
38%
62%
102 / 342 Classifica in Healthcare
Boston Scientific Corp. Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Boston Scientific Corp.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.